News

Tonian McDonald shares her story during the Glaucoma 360 New Horizons Forum at the Westin St. Francis Hotel in San Francisco to recount her journey as a glaucoma patient.

The company, headquarted in New York and London, named OK-101 as the first IND clearance granted by the FDA for a drug to begin clinical studies specifically to treat NCP

OK-101 is the first IND clearance granted by the FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain.

The trial will evaluate tivozanib eye drops (KHK4951), a small-molecule vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3 tyrosine kinase inhibitor (TKI), in patients in with DME.

Hoskins was a pioneer and leader in the field of ophthalmology and glaucoma, and served as executive vice president of the American Academy of Ophthalmology, founding director and Director Emeritus of the Glaucoma Research Foundation, and a founding director of the American Glaucoma Society.

According to the company, AGTC-501 was generally safe and well-tolerated and showed improvements in visual function at the 12-month analysis. The Phase 2/3 VISTA trial for AGTC-501 in XLRP expected to begin in in the first half of 2024.

A third party report regarding the school’s ophthalmology program showed an environment of “anxiety, apprehension, disappointment, frustration, fear, regret.”

The technology has potential for applications in contact lenses and intraocular implants

Preliminary safety data support a favorable benefit-risk profile at both dose levels. The preliminary efficacy and safety data trending similar to or better than the OPTIC study, in which patients continue to see ongoing clinical benefit through at least 3 years.

The study further defined the relationship between delayed rod-mediated dark adaptation and the status of outer retinal bands on optical coherence tomography.

AAO president will deliver the annual Tullos O. Coston, MD lectureship on June 1, 2024.

Clearside noted in a news release it intends to use the net proceeds from this offering for working capital and general corporate purposes.

Sir Jules Thorn Charitable Trust's investment will support a state-of-the-art, eye health research facility, opening in 2027

The patent further protects Iridex’s intellectual property encompassing laser systems in ophthalmology and related fields.

According to the company, the patent further protects Iridex’s intellectual property encompassing laser systems in ophthalmology and related fields

A team of neuroscientists at Johns Hopkins show how specialized cells signal the presence of light simultaneously in two distinct ways.

An investment from the Sir Jules Thorn Charitable Trust will support a state-of-the-art building, opening in 2027

Toku’s AI technology, CLAiR, has obtained CE and UKCA Marks. CLAiR provides fast, accurate, non-invasive cardiovascular disease (CVD) risk assessments using standard retinal images.

In this episode of EyePod, David Hutton sits down with Neena Haider, PhD, and Arun Upadhyay, PhD, to talk about modifier gene therapy.

According to the company, 4D-150 was well tolerated with a favorable safety profile when evaluated through up to 48 weeks of follow-up, with no significant inflammation observed.

Glenn Yiu, MD, PhD, was chosen for this grant. Yiu is a retinal specialist and clinician-scientist currently a professor of ophthalmology at the University of California, Davis.

Elodie Bousquet, MD, PhD, and international researchers studied type 3 macular neovascularization (T3 MNV) using optical coherence tomography. In 64.5% of 31 eyes with T3 MNV, it developed over soft drusen, showing drusen growth and outer layer thinning before T3 MNV.

How this treatment paradigm could change ocular cell therapy

Massachusetts Eye and Ear researchers came up with a mobile app called All_Aboard, designed to be used along with mainstream GPS systems and focuses on improving micro-navigation.

Dr Baruch Kuppermann discusses interim results from the first in-human Phase 2 RIPPLE-1 Trial of a dexamethasone implant for diabetic macular oedema and retinal vein occlusion.

Baruch Kuppermann, MD, PhD, discusses interim results from the first in-human Phase 2 RIPPLE-1 Trial of a dexamethasone implant for diabetic macular edema and retinal vein occlusion.